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Abstract
The possible zoonotic spread of antimicrobial-resistant bacteria is controversial. This review discusses global molecular epidemiological
data combining both analyses of the chromosomal background, using multilocus sequence typing (MLST), and analyses of plasmid (epi-
somal) extended-spectrum b-lactamase (ESBL)/AmpC genes in Escherichia coli present in humans and animals. For consideration of major
epidemiological differences, animals were separated into livestock and companion animals. MLST revealed the existence of ESBL-produc-
ing isolates thoughout the E. coli population, with no obvious association with any ancestral EcoR group. A similar distribution of major
ESBL/AmpC types was apparent only in human isolates, regardless of their geographical origin from Europe, Asia, or the Americas,
whereas in animals this varied extensively between animal groups and across different geographical areas. In contrast to the diversity of
episomal ESBL/AmpC types, isolates from human and animals mainly shared identical sequence types (STs), suggesting transmission or
parallel micro-evolution. In conclusion, the opinion that animal ESBL-producing E. coli is a major source of human infections is oversim-
plified, and neglects a highly complex scenario.
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Introduction
Escherichia coli is a particularly complex species, having diver-
sified into commensals of the intestinal microbiota and path-
ogenic strains, grouped into pathotypes of partly zoonotic
intestinal pathogenic E. coli and extraintestinal pathogenic
E. coli (ExPEC) [1,2]. Only recently has the role of ExPEC in
severe infections received attention, both from a veterinary clini-
cal perspective and regarding their zoonotic potential [2–5].
The increase in antimicrobial-resistant (AMR) bacteria of
animal origin resembles the process in humans a decade ago
[6–8]. Since the late 1990s, extended-spectrum b-lactamase
(ESBL)-producing and AmpC b-lactamase-producing Entero-
bacteriaceae, in particular E. coli, have emerged globally.
Whereas early ESBLs from humans mainly evolved from
TEM and SHV b-lactamases, the significance of CTX-M-type
enzymes has increased over the last decade. Currently they
represent the most common and still rising ESBL type in
humans [9–11]. Since 2000, the European Antimicrobial
Resistance Surveillance Network has reported a steady
increase in the rates of invasive E. coli and Klebsiella pneumo-
niae isolates resistant to third-generation and fourth-genera-
tion cephalosporins. ESBLs confer resistance to oxyimino-
cephalosporins, and often express a multidrug-resistant phe-
notype, leaving only limited therapeutic options [10]. In addi-
tion, plasmid-mediated AmpC b-lactamases (e.g. CMY and
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CIT) and carbapenemases—so far only seen in human iso-
lates (e.g. KPC, NDM, and OXA-48)—are contributing to
the worrying situation regarding antimicrobial resistance, as
they mediate resistance against almost all available b-lactam
agents [2].
Initially, ESBL/AmpC-producing bacteria were only
observed in human medical practice, but the recent observa-
tion of these bacteria, first in companion animals and increas-
ingly in livestock, has initiated monitoring studies
concentrating on livestock [6,7]. ESBL/AmpC-producing
E. coli isolates are now being found in increasing numbers in
food-producing animals [7,12], leading to the hypothesis that
animals might become infection sources or even reser-
voirs—the natural persistent source of infection—contribut-
ing to the spread of these bacteria. Companion animals are
putatively involved in this vicious cycle, as they often live in
close contact with their owners. As the term reservoir is
used imprecisely, not distinguishing between a temporary
and a persistent infection source, it is hard to follow the
literature [6,8]. Fig. 1 illustrates the transmission path-
ways of AMR bacteria and the possible impact of different
habitats.
This review is mainly dedicated to the habitat ‘animal’
(companion animals and livestock) and its complex interplay
with the habitat ‘human’. Published data on ESBL/AmpC-
producing E. coli and other Enterobacteriaceae are summa-
rized and evaluated, with a focus on available molecular
epidemiological and phylogenetic data for both the chromo-
somal background and acquired episomal b-lactamase types.
The conclusion is that we are far from giving simple and
exhaustive answers to the questions concerning the precise
role of animals in the transfer of ESBL/AmpC-producing
E. coli to humans. However, to the best of our knowledge,
this is currently the most comprehensive consideration of
the occurrence of ESBL/AmpC types and their linkage to
phylogenetic E. coli lineages, with respect to host and
geographical distribution.
General Aspects of the Use of
Antimicrobials and Transfer of AMR
Bacteria
The prudent use of antimicrobials in veterinary and human
medicine is a prerequisite for the successful treatment of
serious infectious diseases, and is thus also a matter of ani-
mal welfare. b-Lactam antibiotics, especially cephalosporins,
also select for ESBL-producing Enterobacteriaceae in animals,
enhancing the risk of the zoonotic transmission of ESBL-car-
rying bacteria and plasmids [13–15]. However, increases in
the numbers of ESBL/AmpC-producing strains of E. coli and
Salmonella spp. also occur without any prior use of cephalo-
sporins [15,16]. The reasons for this are not fully under-
stood, as co-selection and co-resistance do only contribute
partially. In companion animals, as in humans, treatment with
fluoroquinolones has led to an increase in the number of
FIG. 1. Diagram illustrating the transmission
pathways of antimicrobial resistance among
different habitats.
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multiresistant strains [17], and its use on farms would be
expected to exert selective pressure [13]. In contrast, the
impacts of different steps in livestock production needs con-
sideration. In chickens, the percentages of ESBL-producing
E. coli decrease from grandparents to parents and again to
the production level, showing the complexity of the influence
of antimicrobial treatment and the maintenance of AMR bac-
teria in food-producing animals [18].
The use of antimicrobials in livestock needs to be distin-
guished from that in companion and exotic animals, for two
reasons: (i) in general, companion animals live as individuals
or in small groups, leading to individual therapeutic interven-
tions, whereas livestock, in general, is kept in larger groups,
so population-based therapeutics are mostly appropriate; (ii)
companion animals often live in intimate contact with their
owners, enabling the spread of multiresistant and zoonotic
agents between owners and animals much more efficiently,
whereas livestock is raised for the production of food, raising
safety issues, in particular in terms of possible food contamina-
tion [19].
In addition, the infection epidemiology of humans, com-
panion animals and livestock differs significantly, suggesting
different risk factors [6,19–21]. The lack of comparative
monitoring or surveillance studies incorporating both human
and veterinary medicine in the same geographical area hin-
ders the identification of risk factors. Furthermore, the
impact of antimicrobials and resistant bacteria in companion
animals has so far been largely neglected [22]. Despite this
lack of knowledge, policies aimed at reducing the amount of
multiresistant bacteria have been implemented. In the veteri-
nary area, these are (i) monitoring programmes, which are
mostly restricted to livestock, (ii) an EU-wide ban on the use
of growth promoters, initiated in 1999; and (iii) guidelines
for the prudent use of antibiotics. We are not aware of true
surveillance studies, in that the results of monitoring directly
impact on the later use of antimicrobials. Another issue is
the use of distinct antimicrobial classes, both in veterinary
and in human medicine, and the prioritization of each class in
the respective area. A catalogue of criteria identified the
most critical important antimicrobials as cephalosporins
(third and fourth generation), macrolides, and quinolones.
Basically, these should be used in human medical practice
only [23]. Again, these recommendations neglect the differ-
ences between companion/exotic animals and livestock.
The availability and usage of antimicrobials differ between
livestock and companion animals. For small animal popula-
tions or for rare infectious diseases, effective antimicrobials
may simply not be available, owing to lack of approval. Thus,
there is a need for off-label use under specific circumstances,
meaning that, if no medicine is authorized, veterinarians have
to use a particular antimicrobial that is approved in another
country or in the medical area [19]. Any other practice is in
conflict with animal welfare.
Distribution of ESBL/AmpC-producing
E. coli in Livestock and Companion Animals
Until the 1990s, the majority of ESBLs identified in human
clinical isolates were SHV or TEM types [2]. Almost one
decade later, ESBL and AmpC b-lactamases have emerged
worldwide, and CTX-M enzymes have now become the
most widespread type of ESBL [9,10]. A number of studies
have described the occurrence of E. coli producing ESBL/
AmpC in food-producing animals, and strains relevant to
human health are increasingly being isolated also from com-
panion animals [6,7,12,24,25]. The most frequent genes asso-
ciated with this resistance among both groups of animals
encode various CTX-M enzymes, followed by blaTEM-52 and
blaSHV-12; other TEM and SHV types are also observed
(Table S1) [6,7,25]. Among the AmpC b-lactamases, blaCMY-2
is by far the most common, other types having only rarely
been identified (Table S1) [12,25].
Although the first ESBL in humans was identified during a
K. pneumoniae outbreak in a German hospital in 1982, one of
the first clinical ESBLs observed in animals dates back to 2000,
from an SHV-12-producing E. coli isolate from a dog with
recurrent urinary tract infection [26]. The earliest description
of poultry as carriers of ESBLs was by Brin˜as et al. [27], who
observed CTX-M-14-producing, SHV-12-producing and CMY-
2-producing E. coli in the faeces of healthy chickens in Spain
between 2000 and 2001. At almost the same time, in 1999–
2002, the isolation of bacteria carrying CTX-M-14, CTX-M-2
and CMY-2 from healthy poultry was reported in Japan [28].
Studies documenting the occurrence of various ESBL types in
pigs and cattle followed soon after [29].
An overview of studies performed on the occurrence and
the nature of b-lactamase types in various animal species and
humans, respectively, is provided in Tables S1 and S2.
Although by no means complete, these data indicate the
development of AMR bacteria roughly within the last decade.
Based on this, the distribution of ESBL/AmpC enzymes among
E. coli, as the most studied bacterial organism, is illustrated
with respect to geographical and host origin in Fig. 2.
Although most studies are still dedicated to human samples
(Table S2), the second most numerous reports (Table S1; 52
cited publications) concern poultry. Most of these studies are
from European countries, with a prevalence of various ESBL/
AmpC types ranging between 0.6% and 44.7% (Table S1;
Fig. 2). There are also quite a number of reports from Asia,
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with rates from 1.7% to 11.8% of ESBL/AmpC-producing
E. coli and Salmonella spp. in poultry. Data from North and
South America and from African countries seem to be rather
limited, and thus are not included in Fig. 2. However, these
studies ascertain the global occurrence of ESBL/AmpC-pro-
ducing bacteria in poultry (Table S1). Other food-producing
animals, including cattle and pigs, are also either colonized or
infected by such bacteria to varying degrees (Table S1).
The occurrence of ESBL-producing bacteria in companion
animals has been neglected for a long time, but a growing
burden is now being observed, especially in dogs, cats, and
horses, with most of the 30 studies listed in Table S1 having
been published within the past 5 years [6,8,30–32]. Initial
data on the prevalence, in particular, of ESBL-producing
E. coli from companion animals indicate high carriage and
infection rates (Table S1). Both diseased and healthy animals
are affected, raising animal welfare and public health issues.
This deserves more attention in future surveillance, as the
extent and genetic basis of AMR bacteria in companion ani-
mals are poorly understood.
ESBL/AmpC Types Reported in E. coli
From Livestock and Companion Animals
It is far too early to judge the direction of transmission of
ESBL/AmpC-producing bacteria between humans and animals
in general. An important part of the global success of, for
example, CTX-M ESBLs is the wide dissemination of particu-
lar plasmids or bacterial clones [9]. Thus, apart from a com-
mon ancestry of ESBL carriers, a central issue is the sharing
of identical plasmid b-lactamase types by humans and animal
hosts, which has recently been reviewed [15,33]. Therefore,
this review will focus on ESBL/AmpC types only.
Fig. 2 shows the distribution of ESBL/AmpC types in E. coli
originating from four different habitats and three different
geographical regions. Irrespective of the group considered,
two to a maximum of three ESBL/AmpC types always pre-
dominate, without overall congruence. The most frequent
types are CTX-M-1, CTX-M-14, CTX-M-15, SHV-12, and
CMY-2. A similar distribution of ESBL/AmpC types is only
FIG. 2. Spatial and host distribution of Escheri-
chia coli extended-spectrum b-lactamase
(ESBL)/AmpC types with regard to data and
the references given in Tables S1 and S2.
With the exception of the category ‘Compan-
ion animals—Asia’, all pie charts presented are
based on a minimum number of eight studies.
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seen in humans, CTX-M-14 and CTX-M-15 being the major
types regardless of geographical origin. One type is broadly
disseminated among animals in Europe, namely CTX-M-1
(companion animals, 28%; poultry, 28%; cattle and pigs, 72%),
whereas it is only rarely reported in other regions and habi-
tats. In general, CTX-M-14 is among the most prevalent b-
lactamase types in companion animals and poultry in Asia
(30–33%), and to a lesser extent in cattle and pigs (14%). It
is less prevalent in livestock (4–7%) in Europe, and is even
absent in companion animals.
CTX-M-15, which has spread pandemically in humans [9],
was only detected incidentally in poultry in European coun-
tries, whereas companion animals (15%) and cattle/pigs (8%)
are frequently associated with this type. In Asian and Ameri-
can countries, this enzyme is present in bacteria from all
groups of animals studied. Although ESBL types are highly
diverse, one episomal AmpC variant, CMY-2, has been
described in all areas and hosts investigated (Table S1;
Fig. 2), its frequency ranging from 2% to 31%.
Hence, a similar distribution of ESBL types is only found in
humans; for the animal groups, the observed patterns are
highly diverse and incongruent. The same is true in terms of
geography. With the exception of CTX-M-14 in Asia, none
of the ESBL types predominates over all other animal and
human groups in one particular area.
CTX-M-1, as a major ESBL type in cattle and pigs in Europe,
amounts to 72% of all ESBLs, and is also frequent in poultry
and companion animals. CTX-M-1-producing E. coli accounts
for 7% of all types identified among humans in Europe only.
Nevertheless, two recent studies from The Netherlands iden-
tified CTX-M-1 as the most prevalent ESBL type shared by
human patients, healthy carriers, poultry, and retail chicken
meat, suggesting recent cross-transmission between human
and avian hosts [24,34]. A relationship between contamination
of chicken meat and the appearance of ESBL genes in humans,
and thus transmission of ESBL-producing E. coli from poultry to
humans, was also suggested, although without unequivocal proof.
The literature gives limited evidence for the spread of ESBL/
AmpC-carrying organisms via direct contact with livestock [15].
In summary, the collective data of the available studies reveal
considerable differences in ESBL types between poultry and
humans in Europe, leaving the question open as to what extent
livestock contributes to the spread of ESBL in humans.
Human and Animal ESBL/AmpC-producing
E. coli Share Identical Phylogenetic Lineages
Partial overlap of b-lactamase types and/or plasmid scaffolds
from human ESBL/AmpC-producing E. coli with those of ani-
mal origin might indicate ongoing interspecies transmission,
but also parallel independent micro-evolution. A sound anal-
ysis of the putative zoonotic nature of such isolates is only
possible by additional typing of the chromosomal back-
ground. Multilocus sequence typing (MLST) reflects micro-
evolution of the E. coli core genome, providing a true
sketch of the population structure of this bacterial species
[35].
In 2008, MLST investigation revealed a pandemic clone,
B2-O25b:H4-ST131-CTX-M-15, with high extraintestinal vir-
ulence, causing urinary tract infections, bacteraemia, urinary
sepsis, and neonatal sepsis [36,37]. Sequence type (ST)131 is
the most studied phylogenetic lineage in terms of antimicro-
bial resistance in E. coli (Figs 3 and 4). Soon after the first
discovery of ESBL-producing ST131 E. coli in human clinical
isolates, it disseminated to various animal species, including
poultry, cattle, pigs, wildlife, and companion animals, and sev-
eral studies suggested transmission from poultry or retail
chicken, but without clear evidence [11,24,38–40].
With the increasing awareness that companion animals
suffer from extraintestinal infections caused by E. coli phylo-
types identical to those that infect humans, the recovery of
ST131, in fact a typical ExPEC lineage, from this animal group
is reasonable [11,41]. Accordingly, we recently confirmed
the presence of CTX-M-15-producing and SHV-12-producing
ST131 E. coli in dogs, cats, and one horse [39]. Ongoing typ-
ing of clinical strains from companion animals (unpublished
data) have demonstrated similar rates of ST131 in the past
2 years, whereas the diversity of CTX-M types is increasing
over time and with the number of isolates (Table 1). This
corroborates data indicating that, in the past few years,
although still mainly associated with CTX-M-15, human clini-
cal ST131 strains have acquired various ESBL genes linked to
plasmids of growing complexity, as assessed by Inc/rep typing
and plasmid MLST, and have diversified in terms of other
transferable resistance elements [37].
ST131 ancestrally derived from EcoR B2, which contains
highly virulent ExPEC, and its combination of multiresistance
and virulence is discussed as likely reason for the pandemic
success of this ST [2,37,41]. The paradigm that maintenance
of antibiotic resistance and high levels of virulence ultimately
lead to loss of bacterial fitness is false for ST131, corrobo-
rating numerous reports on bacteria that have ameliorated
the costs of resistance, e.g. by compensatory mutations
[41,42]. However, attributing the success of ST131 simply to
its virulence would draw a distorted picture [43]. If virulence
is a major driver of the emergence and supposed repeated
selection of AMR ST131 and local variants, why, then, have
other highly virulent ExPEC lineages failed to benefit from
this combination? For example, B2-ST complex (STC)95,
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which is currently represented by 351 strains either depos-
ited in the web-hosted database (http://mlst.ucc. ie/mlst/mlst/
dbs/Ecoli/) or reported in publications, represents one of the
most virulent groups of globally distributed ExPEC strains
[4,5,35,44]. However, only marginal proportions (4%) of
STC95 strains harbour ESBL genes (Table 1; Fig. 4). This is
also the case for B2-STC73 (3.6%) and for other ExPEC-B2
strains known to express a comparable set of ExPEC-related
virulence determinants as observed in ST131 strains, such as
STC127 (4.3%), STC141 (1.1%), and STC372 (0%) (propor-
tions calculated according to the MLST database, data given
in Table 1, and our own unpublished data) [43]. Humans and
poultry are the main hosts of STC95 strains, accounting for
74.4% and 24.2% of all recorded strains, respectively. Septi-
caemia is the main clinical outcome that is relevant for
human patients and poultry flocks, and a zoonotic nature of
avian pathogenic E. coli of STC95 is frequently discussed [45].
If antimicrobial agents favoured the selection of ESBL/AmpC-
producing bacteria in the poultry host, this would, in turn,
lead to an increased risk of humans acquiring these strains
via consumption of contaminated food. Why is STC95, which
is such a well-established and clinically successful phyloge-
netic lineage, less prone to such an event than its B2-ExPEC
‘relative’ STC131? Clearly, future detailed investigations are
needed to answer this question.
Taking a closer look at the distribution of ancestral groups
and the occurrence of ESBL/AmpC-producing bacteria in the
phylogenetic background of >7700 E. coli strains shown in
Fig. 3, it becomes apparent that multiresistant strains are dis-
persed over the entire population. Different STs have
recently been identified among ESBL-producing E. coli linked
to various ancestral groups, such as D (STC38, ST405, and
FIG. 4. Proportion (%) of extended-spectrum b-lactamase (ESBL)/
AmpC/NDM-producing Escherichia coli among the total number of
strains recorded among various sequence type complexes (STCs).
FIG. 3. Minimum spanning tree (MSTree, calculated with Bionumerics 6.6 (Applied Maths, Sint-Martens-Latem, Belgium)) showing the population
structure of 7766 Escherichia coli strains based on allele sequence combinations of genes adk, fumC, purA, recA, gyrB, icd, and mdh. The distribution
of the phylogenetic/ancestral groups, as determined by structure analysis and based on the concatenated sequences of the seven allele sequences,
is shown on the left, and the distribution of extended-spectrum b-lactamase (ESBL)/AmpC/NDM-1-producing E. coli (n = 1863) in the back-
ground of the E. coli population is presented on the right. For multilocus sequence typing (MLST) data and information about the ESBL status of
the strains, see the MLST database (http://mlst.ucc.ie/mlst/mlst/dbs/Ecoli/) (Table S3 (including relevant references), Data S1 (providing available
references for MLST data), and own unpublished results.
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STC69), A (ST10, ST167, and ST617), B1 (ST410), and
hybrid ABD (ST648) (Tables 1 and S3). However, similar to
the situation observed among group B2 complexes, the accu-
mulation of multiresistant strains in certain non-B2 STCs
known to cover strains of intermediate (ancestral group D,
ABD) or low extraintestinal virulence (groups B1 and A) dif-
fers noticeably (Fig. 4) [35,41]. Although the data presented
are just a snapshot of a highly complex and dynamic process,
they highlight the fact that some groups, such as STC648
(ancestral group ABD; 71.1% ESBL/AmpC-producing strains),
STC405 (D; 71.6%), and STC38 (D; 73.6%), have a higher
proportion of multiresistant strains than others, e.g. STC69
(D; 9.4%), STC23 (B1; 29.3%), and STC10 (A; 24.9%). With
respect to the varying virulence gene content of the phyloge-
netic lineages discussed, one might speculate about common,
so far unidentified, genetic factors located in the core gen-
ome that give rise to the increased ability of such strains to
acquire and retain resistance plasmids. As the clinical rele-
vance of most of the non-B2 ExPEC groups has significantly
increased only with the recognition of their multiresistant
phenotype (Table 1), we are just at the very beginning of
unravelling the underlying mechanisms.
As strains of various clonal groups are circulating widely,
they are prone to acquire whatever resistance plasmids are
TABLE 1. Phylogenetic lineages associated with the spread of extended-spectrum b-lactamase (ESBL), and AmpC b-lactamase
genes in Escherichia coli according to the multilocus sequence typing database (http://mlst.ucc.ie/mlst/mlst/dbs/Ecoli), published
data (for references see Table S3), and own unpublished results
Sequence type
complex (STC) and
sequence type (ST) (no.
of strains reported)
Type of
b-lactamase
gene
Confirmed presence (x) in: Spread in:
Companion
animals
Livestock
animals Wildlife Humans Animals Humans
STC131 (n = 995)
ST131 (B2) (n = 983)
Nine other STs (n = 12)
blaCTX-M-3,9,14,15,27,32
blaSHV-5,7,12
blaCIT type
blaNDM-1
xa x x x Globala Global
STC648 (n = 119)
ST648 (ABD) (n = 101)
Ten other STs (n = 18)
blaCTX-M-14,15,32
blaCIT type
blaNDM-1
xa xa x x Globala Global
STC405 (n = 101)
ST405 (D) (n = 94)
Six other STs (n = 7)
blaCTX-M-3,14,15
blaCTX-M group 1
blaCIT type
blaNDM-1
xa x x Europea Global
STC38 (n = 81)
ST38 (D) (n = 68)
ST315 (D) (n = 13)
blaCTX-M-1,9,14,15,27
blaOXA-48
blaNDM-1
xa x x Europea Global
STC101 (n = 43)
ST101 (B1) (n = 21)
ST359 (AxB1) (n = 17)
Two other STs (n = 5)
blaCTX-M-14,15
blaCTX-M group 1
blaCIT type
blaNDM-1
xa x x Europea Europe, Asia, Africa
STC31 (n = 30)
ST393 (D) (n = 28)
Two other STs (n = 2)
blaCTX-M-14,15 x
a x Germanya Global
STC23 (n = 85)
ST410 (B1) (n = 42)
ST23 (B1) (n = 10)
ST88 (B1) (n = 10)
ST90 (B1) (n = 9)
11 other STs (n = 14)
blaCTX-M-1,3,14,15
blaSHV-12,44
blaNDM-1
blaTEM-52
x x x x Europea Global
STC117 (n = 18)
ST117 (ABD) (n = 16)
Two other STs (n = 2)
blaCTX-M-1,2,14,15 x
a x x Europea Europe, Asia
STC10 (n = 174)
ST10 (A) (n = 56)
ST167 (A) (n = 33)
ST617 (A) (n = 25)
47 other STs (n = 60)
blaCTX-M-1,2,14,15
blaSHV-5,12
blaTEM-52
xa xa x x Globala Global
STC69 (n = 15)
ST69 (D) (n = 12)
ST106 (D) (n = 3)
blaCTX-M-1-14 x
a xa x x Europea Global
STCs of non-STC131 B2 lineages only sporadically associated with the spread of ESBL-producing E. coli
STC95 (n = 14)
ST95 (B2) (n = 10)
Three other STs (n = 4)
blaCTX-M-3,14,15 x – Global
STC73 (n = 11)
ST73 (B2) (n = 6)
ST638 (B2) (n = 4)
ST458 (B2) (n = 1)
blaCTX-M-14,15 x
a xa x Germanya Global
aAccording to our own unpublished data, marked STCs also occur in various animal species throughout Europe: STC648 (blaCTX-M-1,3,14,15,61; group 9) and STC23 (blaCTX-M-
1,2,14,15,32) in dogs, cats, horses, and cattle; STC10 (blaCTX-M-1,2,14,15,32) in dogs, cats, horses, cattle, pigs, and birds; STC405 (blaCTX-M-3,14,15,61; group 9) and STC131 (blaCTX-M-
1,2,14,15,27,55) in dogs, cats, horses, and cattle; STC38 (blaCTX-M-3,14) in dogs; STC69 (blaCTX-M-1,15) in dogs and cattle; STC73 (blaCTX-M-1) in cats and cattle; STC117
(blaCTX-M-1) in cats; STC101 (blaCTX-M-14) in cats and dogs.
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locally prevalent [46]. Accordingly, although distributions
may differ from case to case, an exclusive linkage of one bla
gene or a distinct host with a certain ST or STC is not evi-
dent (Table 1). Given that animal strains constitute only a
low proportion (<20%) of ESBL-producing E. coli isolates
analysed with MLST, it is even more intriguing that these iso-
lates mainly share identical phylotypes with human strains,
suggesting frequent and continuous interspecies transmission.
However, only more discriminative typing tools can provide
further support for this hypothesis. The schedule of events,
i.e. the first appearance of ESBL-producing bacteria in the
medical context and the earlier recovery of prominent phyl-
otypes, such as ST131, from humans, might (mis)lead us into
thinking that the initial transfer of multiresistant strains was
from humans to animals. The molecular epidemiological data
are just as tentative as the growing discussion about live-
stock as the primary infection source of such bacteria.
Conclusions
We have discussed global molecular epidemiological data on
ESBL/AmpC-producing E. coli by comparing phylotypes with
episomal resistance genes in different hosts. Owing to the
lack of data on incompatibility groups of plasmids in concert
with MLST and ESBL/AmpC types, these were not included.
Also, data from single continents were excluded because of
a limited number of publications. Most importantly, the simi-
larity of major ESBL/AmpC types and STs in humans regard-
less of their geographical origin points towards person-to-
person transmission as the most important route of antimi-
crobial resistance distribution. Whether the initial spread of
such strains from humans as original carriers was the source
of the latter enrichment of CTX-M-producing E. coli in ani-
mals remains unknown. However, the primary occurrence of
CTX-M-1 points in this direction, at least in Europe.
Apart from this, the analysed data raise more questions
than answers. Defining routes and directions of transmission
is possible, as all of the molecular methods needed are at
hand, up to whole genome next-generation sequencing.
However, these methods need to be applied in parallel in
medical and veterinary areas. If harmonized protocols are
used within a given time and geographical area, the flow of
ESBL-producing E. coli can be traced. At the same time,
detailed knowledge of antimicrobial usage in humans,
livestock and companion animal populations should be
recorded. As such data are currently missing, improved par-
allel monitoring and surveillance programmes are desperately
needed.
Furthermore, a more sound understanding of horizontal
gene flow between different E. coli and related Enterobacteria-
ceae strains is needed. Our collection of MLST data of
>7700 E. coli strains revealed plasmids encoding ESBL/AmpC
genes over the whole E. coli population, showing highly pro-
miscuous gene transfer, which can hardly be controlled.
Would competitive exclusion with probiotics be an option
to reduce intestinal ESBL/AmpC-producing strains? Or could
we even vaccinate against these bacteria? To tackle this chal-
lenge, we also need a more comprehensive understanding of
the mechanisms of colonization as well as antimicrobial resis-
tance. Currently, the increase in ESBL/AmpC-producing
E. coli is mainly considered to be a consequence of the over-
use of antimicrobials. Although we do not argue against this
obvious fact, which makes the prudent use of antimicrobials
mandatory, the additional factors involved need to be unrav-
elled. Pandora’s Box has been opened, but rather than
continuing with the ‘name, shame and blame’ approach, it is
more straightforward to encourage interdisciplinary and
novel strategies in the spirit of ‘One Health’.
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